{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:22:41Z","timestamp":1761578561610},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T00:00:00Z","timestamp":1309219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00280-011-1690-0","type":"journal-article","created":{"date-parts":[[2011,6,27]],"date-time":"2011-06-27T20:24:15Z","timestamp":1309206255000},"page":"309-315","source":"Crossref","is-referenced-by-count":34,"title":["Imatinib mesylate in thymic epithelial malignancies"],"prefix":"10.1007","volume":"69","author":[{"given":"Giovannella","family":"Palmieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Buonerba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Petillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Lalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ceribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardina","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elide","family":"Matano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Sioletic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,28]]},"reference":[{"key":"1690_CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","volume":"44","author":"WK Jong De","year":"2008","unstructured":"De Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ (2008) Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 44:123\u2013130","journal-title":"Eur J Cancer"},{"key":"1690_CR2","unstructured":"Travis WD, Brambilla E, M\u00fcller-Hemerlink HK (2004) Tumours of the lung, pleura, thymus and heart. In: Pathology & Genetics series, World Health Organization Classification of Tumours, IARC Press, Lyon"},{"key":"1690_CR3","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","volume":"48","author":"A Masaoka","year":"1981","unstructured":"Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485\u20132492","journal-title":"Cancer"},{"key":"1690_CR4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","volume":"4","author":"CB Falkson","year":"2009","unstructured":"Falkson CB, Bezjak A, Darling G et al (2009) The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 4:911\u2013919","journal-title":"J Thorac Oncol"},{"key":"1690_CR5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","volume":"21","author":"G Palmieri","year":"2010","unstructured":"Palmieri G, Merola G, Federico P et al (2010) Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 21:1168\u20131172","journal-title":"Ann Oncol"},{"key":"1690_CR6","doi-asserted-by":"crossref","unstructured":"Blay JY (2010) A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. [Epub ahead of print]","DOI":"10.1016\/j.ctrv.2010.11.003"},{"key":"1690_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.humpath.2007.03.001","volume":"38","author":"JL Hornick","year":"2007","unstructured":"Hornick JL, Fletcher CD (2007) The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38:679\u2013687","journal-title":"Hum Pathol"},{"issue":"9","key":"1690_CR8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/JTO.0b013e3181e96e30","volume":"5","author":"I Petrini","year":"2010","unstructured":"Petrini I, Zucali PA, Lee HS (2010) Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol 5(9):1447\u20131453","journal-title":"J Thorac Oncol"},{"key":"1690_CR9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","volume":"128","author":"K Nakagawa","year":"2005","unstructured":"Nakagawa K, Matsuno Y, Kunitoh H et al (2005) Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128:140\u2013144","journal-title":"Chest"},{"issue":"25","key":"1690_CR10","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","volume":"350","author":"P Str\u00f6bel","year":"2004","unstructured":"Str\u00f6bel P, Hartmann M, Jakob A et al (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350(25):2625\u20132626","journal-title":"N Engl J Med"},{"key":"1690_CR11","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342\u20134349","journal-title":"J Clin Oncol"},{"key":"1690_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1690_CR13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127\u20131134","journal-title":"Lancet"},{"key":"1690_CR14","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773\u20131782","journal-title":"Eur J Cancer"},{"issue":"6","key":"1690_CR15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","volume":"20","author":"RP A\u2019Hern","year":"2001","unstructured":"A\u2019Hern RP (2001) Sample size tables for exact single-stage phase II designs. Stat Med 20(6):859\u2013866","journal-title":"Stat Med"},{"key":"1690_CR16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/373347a0","volume":"373","author":"JD Huizinga","year":"1995","unstructured":"Huizinga JD, Thuneberg L, Kl\u00fcppel M, Malysz J, Mikkelsen HB, Bernstein A (1995) W\/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373:347\u2013349","journal-title":"Nature"},{"issue":"3","key":"1690_CR17","first-page":"349","volume":"73","author":"J Paral","year":"2010","unstructured":"Paral J, Slaninka I, Kalabova H, Hadzi-Nikolov D (2010) Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options. Acta Gastroenterol Belg 73(3):349\u2013359","journal-title":"Acta Gastroenterol Belg"},{"issue":"10","key":"1690_CR18","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.21000","volume":"103","author":"LM Krug","year":"2005","unstructured":"Krug LM, Crapanzano JP, Azzoli CG et al (2005) Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103(10):2128\u20132131","journal-title":"Cancer"},{"issue":"3","key":"1690_CR19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2005.06.125","volume":"23","author":"SJ Hotte","year":"2005","unstructured":"Hotte SJ, Winquist EW, Lamont E et al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23(3):585\u2013590","journal-title":"J Clin Oncol"},{"issue":"2","key":"1690_CR20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ygyno.2010.01.002","volume":"117","author":"WK Huh","year":"2010","unstructured":"Huh WK, Sill MW, Darcy KM et al (2010) Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a gynecologic oncology group phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 117(2):248\u2013254","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1690_CR21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/JTO.0b013e3181f209b9","volume":"10","author":"N Girard","year":"2010","unstructured":"Girard N (2010) Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 10(4):291\u2013295","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1690_CR22","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","volume":"4","author":"G Giaccone","year":"2009","unstructured":"Giaccone G, Rajan A, Ruijter R et al (2009) Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 4(10):1270\u20131273","journal-title":"J Thorac Oncol"},{"key":"1690_CR23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2010.09.011","volume":"71","author":"U Di\u015fel","year":"2011","unstructured":"Di\u015fel U, Oztuzcu S, Be\u015fen AA et al (2011) Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 71:109\u2013112","journal-title":"Lung Cancer"},{"key":"1690_CR24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","volume":"103","author":"P Str\u00f6bel","year":"2010","unstructured":"Str\u00f6bel P, Bargou R, Wolff A et al (2010) Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 103:196\u2013200","journal-title":"Br J Cancer"},{"key":"1690_CR25","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","volume":"15","author":"N Girard","year":"2009","unstructured":"Girard N, Shen R, Guo T et al (2009) Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 15:6790\u20136799","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1690-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1690-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1690-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T08:17:28Z","timestamp":1560327448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1690-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,28]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1690-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,28]]}}}